A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients With Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Disease Free Survival (DFS)
Approximately 5 years
No
Boehringer Ingelheim
Study Chair
Boehringer Ingelheim Pharmaceuticals
Argentina: Admin Nacional de Medicamentos, Alimentos Tecnologia Medica
1200.131
NCT01345669
October 2011
May 2019
Name | Location |
---|---|
1200.131.00178 Boehringer Ingelheim Investigational Site | Los Angeles, California |
1200.131.00181 Boehringer Ingelheim Investigational Site | Orange, California |
1200.131.00187 Boehringer Ingelheim Investigational Site | New Orleans, Louisiana |
1200.131.00182 Boehringer Ingelheim Investigational Site | Omaha, Nebraska |
1200.131.00175 Boehringer Ingelheim Investigational Site | Lebanon, New Hampshire |
1200.131.00179 Boehringer Ingelheim Investigational Site | Stony Brook, New York |
1200.131.00184 Boehringer Ingelheim Investigational Site | San Antonio, Texas |
1200.131.00183 Boehringer Ingelheim Investigational Site | Wenatchee, Washington |
1200.131.00171 Boehringer Ingelheim Investigational Site | Little Rock, Alaska |
1200.131.00177 Boehringer Ingelheim Investigational Site | Aurora, Colorado |
1200.131.00185 Boehringer Ingelheim Investigational Site | New Haven, Connecticut |
1200.131.00191 Boehringer Ingelheim Investigational Site | Harvey, Illinois |
1200.131.00173 Boehringer Ingelheim Investigational Site | Baltimore, Maryland |
1200.131.00176 Boehringer Ingelheim Investigational Site | Boston, Massachusetts |
1200.131.00190 Boehringer Ingelheim Investigational Site | Boston, Massachusetts |
1200.131.00188 Boehringer Ingelheim Investigational Site | Bronx, New York |
1200.131.00189 Boehringer Ingelheim Investigational Site | Cleveland, Ohio |
1200.131.00172 Boehringer Ingelheim Investigational Site | Philadelphia, Pennsylvania |